SCHEMBL4727700

SCHEMBL4727700

Fc1ccc(NC(=S)c2ccc(-c3ccccc3)cc2)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.58
KMT2A Q03164 7/20 0.58
MAPT P10636 7/20 0.58
ALDH1A1 P00352 6/20 0.58
HTT P42858 3/20 0.58
NPSR1 Q6W5P4 2/20 0.58
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
GAA P10253 2/20 0.53
LMNA P02545 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
SLC2A1 P11166 1/20 0.47
FADS1 O60427 1/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
MAPK1 P28482 1/20 0.46
POLB P06746 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14261340 0.91 NPC1 (0.68) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL14261422 0.83 NPC1 (0.57) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL4730328 0.83 NPC1 (0.57) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL4730330 0.83 NPC1 (0.57) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL4725605 0.83 NPC1 (0.83) MEN1KMT2AMAPTNPSR1NPC1
SCHEMBL20560699 0.73 KMT2A (0.76) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL1437418 0.73 NPC1 (0.68) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL22223416 0.72 RAB9A (0.68) MEN1KMT2AMAPTALDH1A1NPSR1
SCHEMBL1043172 0.72 ESR2 (0.57) NPC1RAB9A
SCHEMBL11596948 0.72 KMT2A (0.73) MEN1KMT2AMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119491-A1 AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-22 US disclosed
US-20080119491-A1 AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-22 US disclosed
US-20080119491-A1 AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-22 US disclosed
WO-2008036643-A2 AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119491-A1 AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT MEN1 1772/4885KMT2A 1256/4885MAPT 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.